Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 0.62 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nandrolone Decanoate SCHEMBL6151508 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL19834508 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL3803109 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL11593159 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL14568852 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL16107220 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL11351978 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL10710160 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| SCHEMBL3850364 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 | |
| Nandrolone Decanoate SCHEMBL30692744 | 1.00 | MAPT (1.00) | MAPTLMNAARSERPINA6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940151-B2 | Methods for treating renal disease | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-03-09 | — | — | US | claimed |
| US-20190117659-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2019-04-25 | — | — | US | claimed |
| US-10130632-B2 | Methods for treating renal disease | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2018-11-20 | — | — | US | claimed |
| US-20180169069-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2018-06-21 | — | — | US | claimed |
| US-20150297598-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-10-22 | — | — | US | claimed |
| WO-2014085154-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2014-06-05 | — | — | WO | claimed |
| WO-2012162394-A2 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2012-11-29 | — | — | WO | claimed |
| WO-2011133474-A2 | METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2374458-A1 | Combination of an ACE inhibitor and an NSAID for use in ameliorating cachexia/SIRS | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2374508-A1 | Combination of angiotension receptor blockers (ARB) and NSAIDs for use in ameliorating cachexia | Vicus Therapeutics SPE 1, LLC (US) | 2011-10-12 | — | — | EP | claimed |
| US-20090215852-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | CHROMA GROUP, INC. | 2009-08-27 | — | — | US | claimed |
| US-20090117197-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS LLC (US) | 2009-05-07 | — | — | US | claimed |
| EP-1990049-A2 | Combination therapy of beta-blockers and non-steroidal anti-inflammatory drugs (NSAID) | Vicus Therapeutics SPE 1, LLC (US) | 2008-11-12 | — | — | EP | claimed |
| EP-1865779-A4 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS SPE 1 LLC (US) | 2008-06-04 | — | — | EP | claimed |
| EP-1865779-A2 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | Vicus Therapeutics SPE 1, LLC (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006102476-A2 | COMPOSITIONS AND METHODS FOR AMELIORATING CACHEXIA | VICUS THERAPEUTICS SPE 1, LLC (US) | 2006-09-28 | — | — | WO | claimed |
| US-4083973-A | ANABOLIC ACTIVITY, NANDROLONE | AKZONA INCORPORATED (US) | 1978-04-11 | — | — | US | claimed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| US-4128426-A | GLYCIDYL METHACRYLATE AND/OR ACRYLATE-ALKYL METHACRYLATE AND/OR ACRYLATE COPOLYMER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1978-12-05 | — | — | US | disclosed |
| US-4083973-A | ANABOLIC ACTIVITY, NANDROLONE | AKZONA INCORPORATED (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117659-A1 | METHODS FOR TREATING RENAL DISEASE | LDLR, APOL1, APOB | MAPT 3600/4885LMNA 434/4885AR 3667/4885 |
| US-20150297598-A1 | METHODS FOR TREATING RENAL DISEASE | LDLR, APOL1, APOB | MAPT 3600/4885LMNA 434/4885AR 3667/4885 |
| US-10130632-B2 | Methods for treating renal disease | LDLR, APOL1, APOB | MAPT 3600/4885LMNA 434/4885AR 3667/4885 |
| US-10940151-B2 | Methods for treating renal disease | LDLR, APOL1, APOB | MAPT 3600/4885LMNA 434/4885AR 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.